|Bid||35.92 x 5200|
|Ask||35.93 x 1600|
|Day's Range||35.81 - 36.21|
|52 Week Range||29.83 - 36.21|
|PE Ratio (TTM)||26.25|
|Dividend & Yield||1.28 (3.62%)|
|1y Target Est||N/A|
The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful ...
On September 1, 2017, the FDA approved Pfizer's drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.
Shares of Pfizer (PFE) have made quite a run in recent weeks. Morgan Stanley’s David Risinger says the drug’s giant’s stock should keep rising, perhaps as high as $44 a share. Earlier today, Risinger upgraded Pfizer from an Equal-weight to an Outperform and set a $39 price target, which is based on a price-to-earnings multiple of 14 times 2018 estimated earnings of $2.76 a share.